Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
To investigate the association of initial brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) with the detection of sepsis-induced myocardial dysfunction (SIMD) in the setting of Sepsis 3.0. Three databases were searched to analyze initial BNP and NT-proBNP levels between SIMD and non-SIMD groups. Eighteen studies were included, most of which defined SIMD based on echocardiography. The SIMD group exhibited higher initial BNP and NT-proBNP levels in blood. NT-proBNP higher than a certain cutoff value (>3000 pg/ml) was an independent risk factor for SIMD and its accuracy for SIMD diagnosis was moderate (pooled area under the curve: 0.81). Initial blood BNP and NT-proBNP levels are useful to assist in the detection of SIMD and further studies are warranted to determine the SIMD definition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/bmm-2023-0605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of traditional Chinese exercises on the rehabilitation of patients with chronic heart failure: A -analysis.
Int J Cardiol Heart Vasc
October 2025
School of Wushu, Wuhan Sports University, Wuhan 430079, China.
The systematic -analysis was conducted to evaluate the clinical efficacy of Traditional Chinese Exercises (TCE) in the rehabilitation of patients with chronic heart failure (CHF). The findings provide evidence-based support for the implementation of non-pharmacological interventions in the management of CHF. A systematic search of PubMed, Web of Science, Cochrane Library, and Embase (up to November 2024) identified RCTs evaluating Traditional Chinese Exercise (TCE) for chronic heart failure rehabilitation.
View Article and Find Full Text PDFA Proposal to Elevate the Status of Troponin and B-Type Natriuretic Peptides as Atherosclerotic Cardiovascular Disease Risk Enhancers.
Circulation
September 2025
Sections of Cardiovascular Research and Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX (V.N., C.M.B.).
Early diagnostic utility of BNP and NT-proBNP for cardioembolic stroke: A head-to-head comparison in the hyperacute and early acute phase.
J Clin Neurosci
August 2025
Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address:
Background: Cardioembolic (CE) stroke is a common and often severe subtype of ischemic stroke, but early and accurate differentiation from other stroke types remains challenging. Brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) have emerged as promising biomarkers, yet direct comparative studies evaluating their diagnostic utility in the hyperacute and early acute phase are limited.
Methods: This prospective study included 165 patients who presented with acute stroke symptoms within twenty-four hours of onset at a single tertiary center.
Potential of Pumpkin Pulp Carotenoid Extract in the Prevention of Doxorubicin-Induced Cardiotoxicity.
Pharmaceutics
July 2025
Department of Histology and Embryology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
: Doxorubicin is a chemotherapeutic agent whose clinical use is limited by side effects (SEs). The most common SE is doxorubicin-induced cardiotoxicity (DIC), for which there is still no prevention. The hypothesis arises that active substances of natural origin could influence DIC prevention by affecting several pathways of DIC occurrence.
View Article and Find Full Text PDFDose-dependent renoprotective effects of sacubitril/valsartan in heart failure: a retrospective study.
Ren Fail
December 2025
Department of Pharmacy, Kochi Medical School Hospital, Kochi, Japan.
To evaluate the dose-dependent renoprotective effects of sacubitril/valsartan in heart failure patients. This retrospective observational study included patients with heart failure (Stage B or higher, B-type natriuretic peptide (BNP) >100 pg/mL or N-terminal proBNP >300 pg/mL) who initiated sacubitril/valsartan (SV) treatment. Patients were classified by final SV daily dose (50, 100, 200, or 400 mg) at 18 months.
View Article and Find Full Text PDF